Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression

NCT06977061 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Gastric Neoplasm

Interventions

DRUG: Fruquintinib Combined with Sintilimab and Stereotactic Body Radiation Therapy

Sponsor

Queling Liu